Key Highlights

  • Biome Australia Ltd (ASX: BIO) reported record FY26 annual sales revenue of $23.9 million, representing 30% growth compared with FY25.
  • Consumer sell-through of Activated Probiotics exceeded 100,000 units in June 2026, marking a new company milestone.
  • Biome Daily became the number one probiotic product in Australian pharmacies by both unit sales and dollar value.
  • The company increased cash reserves to $3.6 million, reduced debt by $1 million year-on-year, and signed a manufacturing agreement to bring production onshore.

Biome Australia Ltd (ASX: BIO) has drawn renewed investor attention after reporting a record financial year, with its latest quarterly update highlighting accelerating sales growth, improved cash generation and progress across its microbiome health product portfolio.

The company's shares were trading at A$0.28, gaining 8.33% during the latest session. Despite the recent improvement, BIO remains approximately 50% lower over the past year, reflecting the challenges faced by many emerging healthcare companies as investors reassess growth expectations and market conditions.

The company's 29 July 2026 Quarterly Activities Report and Appendix 4C outlined a year of operational progress, with FY26 annual sales revenue reaching a record level and several strategic initiatives advancing under its Vision 27 growth plan.

Share Performance Reflects Changing Investor Sentiment

Biome Australia's share price performance over the past year highlights a gap between operational progress and market valuation sentiment.

While the company has achieved stronger revenue growth and increased brand recognition, the stock remains significantly below levels seen a year earlier. The recent share price recovery suggests some investors are responding positively to improving business metrics, particularly the company's sales momentum and improved cash position.

For healthcare companies operating in consumer health categories, market confidence is often influenced by the ability to convert product demand into sustainable revenue growth and improved financial performance.

The latest quarterly update provides investors with additional information on Biome's commercial progress and its pathway toward expanding its product presence.

FY26 Revenue Growth Reaches Record Levels

The central feature of Biome's latest announcement was its record annual sales performance.

The company reported:

  • FY26 annual sales revenue of $23.9 million.
  • Revenue growth of 30% compared with FY25 revenue of $18.4 million.

Management attributed the increase to continued demand from healthcare practitioners and pharmacies for the company's Activated Probiotics and Activated Therapeutics product ranges.

The company also reported that June 2026 represented a significant milestone, with consumer sell-through of Activated Probiotics exceeding 100,000 units for the first time.

This growth indicates increasing consumer adoption of Biome's products across its target markets.

Biome Daily Achieves Leading Pharmacy Position

A major development during the quarter was the company's announcement that Biome Daily had become the number one probiotic product in Australian pharmacy by both units sold and dollar value.

The ranking was based on IQVIA Sell Out Service data for the vitamins and supplements category, covering the 52 weeks ending 27 June 2026.

For Biome, achieving leading market position for its flagship product represents an important commercial milestone.

The company believes the result highlights further growth potential for the broader Activated Probiotics and Activated Therapeutics ranges, both domestically and internationally.

Expanding from a leading individual product position into wider category growth will likely remain a key focus as the company continues developing its brand portfolio.

Onshore Manufacturing Agreement Supports Vision 27 Strategy

During the quarter, Biome signed a binding manufacturing agreement with Specialty Probiotics Australia (SPA) to bring production of the Activated Probiotics range onshore.

The agreement forms part of the company's Vision 27 strategy and is expected to require no capital investment from Biome.

The first commercial manufacturing batch is targeted for September 2026.

Bringing manufacturing closer to its primary market could provide operational advantages, including supply chain flexibility and improved control over production processes.

The company has positioned this initiative as an important step in supporting future growth without requiring significant additional capital expenditure.

Research Pipeline Continues Through BMB18 Development

Biome also progressed its research and development activities during the quarter, particularly around its proprietary probiotic strain BMB18.

The company lodged a patent application relating to BMB18 during the period, supporting its intellectual property strategy.

The BMB18 clinical trial was expanded internationally, with Harokopio University of Athens becoming the first international clinical centre involved in the study.

Participant recruitment commenced at both the Athens location and La Trobe University in Australia during June.

Clinical development remains an important part of Biome's strategy as the company seeks to build scientific validation around its proprietary products.

Improved Cash Position and Lower Debt

Biome reported further improvement in its financial position during the June quarter.

Key financial updates included:

  • Quarterly cash receipts of $5.9 million.
  • Cash receipts increased by $1.1 million compared with Q3 FY26.
  • Cash receipts increased by $2.2 million, or 61%, compared with the prior corresponding period.
  • Net operating cash inflow of $708,000 for the quarter.
  • Cash balance of $3.6 million at 30 June 2026.
  • Debt reduced by $1 million year-on-year to $1.9 million.

The improvement in cash generation provides additional flexibility as the company continues investing in marketing, product development and commercial expansion.

Full details regarding profitability and margins are expected with the audited FY26 results.

Growth Strategy Focused on Expansion

Biome's latest update demonstrates a business transitioning from product development toward broader commercial expansion.

The company's strategy is centred on increasing adoption of its microbiome health products through pharmacy channels, healthcare practitioners and international markets.

The company continues to focus on expanding its Activated Probiotics and Activated Therapeutics ranges while investing in research initiatives that could support future product development.

However, investors will likely continue monitoring whether revenue growth translates into consistent profitability as the company scales operations.

What Investors Are Watching Next

Following the latest quarterly report, investors are likely to focus on several upcoming developments.

Key areas of interest include:

  • The company's audited FY26 financial results.
  • Progress of the onshore manufacturing transition.
  • Continued sales growth across Activated Probiotics products.
  • Expansion into international markets.
  • Updates from the BMB18 clinical trial program.

The ability to maintain revenue momentum while improving margins and cash generation will remain important factors influencing market sentiment.

Conclusion

Biome Australia Ltd (ASX: BIO) has reported a significant period of operational progress, highlighted by record FY26 revenue, increasing consumer adoption of Activated Probiotics and improvements in its financial position. The company's achievement of pharmacy leadership with Biome Daily, combined with its manufacturing agreement and ongoing clinical development programs, provides several growth initiatives for investors to monitor. However, despite these operational milestones, the share price remains lower over the past year, indicating that the market continues to assess the company's ability to convert growth into sustainable financial performance. Future results, margin improvement and execution of its Vision 27 strategy are likely to remain central to Biome's investment story.